

# Min-jiang Chen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4330367/publications.pdf>

Version: 2024-02-01

47  
papers

1,037  
citations

471061

17  
h-index

476904

29  
g-index

59  
all docs

59  
docs citations

59  
times ranked

1709  
citing authors

#	ARTICLE	IF	CITATIONS
1	Circulating cytokines associated with clinical outcomes in advanced non-small cell lung cancer patients who received chemoimmunotherapy. <i>Thoracic Cancer</i> , 2022, 13, 219-227.	0.8	19
2	Leptomeningeal enhancement in magnetic resonance imaging predicts poor prognosis in lung adenocarcinoma patients with leptomeningeal metastasis. <i>Thoracic Cancer</i> , 2022, 13, 1059-1066.	0.8	2
3	Clinical characteristics and prognostic model for extensive-stage small cell lung cancer: A retrospective study over an 8-year period. <i>Thoracic Cancer</i> , 2022, 13, 539-548.	0.8	5
4	Immune checkpoint inhibitor-related adverse events in lung cancer: Real-world incidence and management practices of 1905 patients in China. <i>Thoracic Cancer</i> , 2022, 13, 412-422.	0.8	19
5	Prognostic Factors and Survival Benefits of Antitumor Treatments for Advanced Non-Small Cell Lung Cancer Patients With Central Nervous System Metastasis With or Without Driver Genes: A Chinese Single-Center Cohort Study. <i>Frontiers in Oncology</i> , 2022, 12, 879554.	1.3	0
6	Prognostic impact of maximum standardized uptake value on 18 F-FDG PET / CT imaging of the primary lung lesion on survival in advanced non-small cell lung cancer: A retrospective study. <i>Thoracic Cancer</i> , 2021, 12, 845-853.	0.8	7
7	Case Report: THSD7A-Positive Membranous Nephropathy Caused by Tislelizumab in a Lung Cancer Patient. <i>Frontiers in Immunology</i> , 2021, 12, 619147.	2.2	18
8	Clinical-radiological characteristics and intestinal microbiota in patients with pancreatic immune-related adverse events. <i>Thoracic Cancer</i> , 2021, 12, 1814-1823.	0.8	10
9	Feasibility and reliability of evaluate PD-L1 expression determination using small biopsy specimens in non-small cell lung cancer. <i>Thoracic Cancer</i> , 2021, 12, 2339-2344.	0.8	6
10	Case report of neurofibromatosis type 1 combined with primary ciliary dyskinesia. <i>Frontiers of Medicine</i> , 2021, , 1.	1.5	2
11	Risk factors for immune-related adverse events: what have we learned and what lies ahead?. <i>Biomarker Research</i> , 2021, 9, 79.	2.8	36
12	Sarcoidosis-like reaction after neoadjuvant pembrolizumab combined with chemotherapy mimicking disease progression of NSCLC induced encouraging discovery of pathological complete response. <i>Thoracic Cancer</i> , 2021, , .	0.8	6
13	Characterization of Somatic Mutations That Affect Neoantigens in Non-Small Cell Lung Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 749461.	2.2	11
14	Correlations between peripheral blood biomarkers and clinical outcomes in advanced non-small cell lung cancer patients who received immunotherapy-based treatments. <i>Translational Lung Cancer Research</i> , 2021, 10, 4477-4493.	1.3	14
15	Clinicopathological characteristics of lung cancer in patients with systemic sclerosis. <i>Clinical Respiratory Journal</i> , 2020, 14, 1131-1136.	0.6	6
16	Positive tumour CD47 expression is an independent prognostic factor for recurrence in resected non-small cell lung cancer. <i>ESMO Open</i> , 2020, 5, e000823.	2.0	11
17	Immunotherapy as second-line treatment and beyond for non-small cell lung cancer in a single center of China: Outcomes, toxicities, and clinical predictive factors from a real-world retrospective analysis. <i>Thoracic Cancer</i> , 2020, 11, 1955-1962.	0.8	16
18	Patterns of response in metastatic NSCLC during PD-L1 or PD-L1 inhibitor therapy: Comparison of the RECIST 1.1 and iRECIST criteria. <i>Thoracic Cancer</i> , 2020, 11, 1068-1075.	0.8	15

#	ARTICLE	IF	CITATIONS
19	Tâ€cell exhaustion interrelates with immune cytolytic activity to shape the inflamed tumor microenvironment. <i>Journal of Pathology</i> , 2020, 251, 147-159.	2.1	25
20	Renal immuneâ€related adverse events of immune checkpoint inhibitor. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, 305-311.	0.7	6
21	Recognition and management of the gastrointestinal and hepatic immuneâ€related adverse events. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, 95-102.	0.7	6
22	<p>Elevated levels of pre-treatment lactate dehydrogenase are an unfavorable predictor factor in patients with EML4-ALK rearrangement non-small cell lung cancer treated with crizotinib</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 8191-8200.	0.9	4
23	Realâ€world data on EGFR/ALK gene status and firstâ€line targeted therapy rate in newly diagnosed advanced nonâ€small cell lung cancer patients in Northern China: A prospective observational study. <i>Thoracic Cancer</i> , 2019, 10, 1521-1532.	0.8	18
24	Concurrent Driver Gene Mutations as Negative Predictive Factors in Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer. <i>EBioMedicine</i> , 2019, 42, 304-310.	2.7	51
25	Thymic neoplasms patients complicated with bronchiectasis: Case series in a Chinese hospital and literature review. <i>Thoracic Cancer</i> , 2019, 10, 791-798.	0.8	7
26	Clinicopathological, microenvironmental and genetic determinants of molecular subtypes in KEAP1/NRF2â€mutant lung cancer. <i>International Journal of Cancer</i> , 2019, 144, 788-801.	2.3	16
27	Association of PFS with levels of pretreatment lactate dehydrogenase in patients with EML4-ALK rearrangement non-small cell lung cancer treated with ALK tyrosine kinase inhibitor.. <i>Journal of Clinical Oncology</i> , 2019, 37, e20513-e20513.	0.8	0
28	Prognostic role of circulating tumor cells in patients with <i>EGFR</i>â€mutated or <i>ALK</i>â€rearranged nonâ€small cell lung cancer. <i>Thoracic Cancer</i> , 2018, 9, 640-645.	0.8	23
29	PI3K in cancer: its structure, activation modes and role in shaping tumor microenvironment. <i>Future Oncology</i> , 2018, 14, 665-674.	1.1	49
30	Paraneoplastic limbic encephalitis associated with lung cancer. <i>Scientific Reports</i> , 2018, 8, 6792.	1.6	29
31	Prospective study revealed prognostic significance of responses in leptomeningeal metastasis and clinical value of cerebrospinal fluid-based liquid biopsy. <i>Lung Cancer</i> , 2018, 125, 142-149.	0.9	34
32	Clinicopathological features of lung cancer in patients with rheumatoid arthritis. <i>Journal of Thoracic Disease</i> , 2018, 10, 3965-3972.	0.6	9
33	Molecular Targeted Therapies Elicit Concurrent Apoptotic and GSDME-Dependent Pyroptotic Tumor Cell Death. <i>Clinical Cancer Research</i> , 2018, 24, 6066-6077.	3.2	178
34	<i>ALK</i>â€rearranged lung cancer with intradural extramedullary spinal cord metastases responding to ceritinib treatment: A case report. <i>Thoracic Cancer</i> , 2018, 9, 1078-1081.	0.8	3
35	Tumor CD47 expression and a high M2/M1 ratio of tumor-associated macrophages as an adverse prognostic factor in resected stage â€câ non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, e20531-e20531.	0.8	1
36	Simultaneous evolutionary expansion and constraint of genomic heterogeneity in multifocal lung cancer. <i>Nature Communications</i> , 2017, 8, 823.	5.8	53

#	ARTICLE	IF	CITATIONS
37	Total DNA input is a crucial determinant of the sensitivity of plasma cell-free DNA EGFR mutation detection using droplet digital PCR. <i>Oncotarget</i> , 2017, 8, 5861-5873.	0.8	41
38	Harness the synergy between targeted therapy and immunotherapy: what have we learned and where are we headed?. <i>Oncotarget</i> , 2017, 8, 86969-86984.	0.8	5
39	Prognostic significance of circulating tumor cells in non-small cell lung cancer patients undergoing chemotherapy. <i>Oncotarget</i> , 2017, 8, 86615-86624.	0.8	32
40	Adaptive and Acquired Resistance to EGFR Inhibitors Converge on the MAPK Pathway. <i>Theranostics</i> , 2016, 6, 1232-1243.	4.6	42
41	A sensitive and practical method to detect the T790M mutation in the epidermal growth factor receptor. <i>Oncology Letters</i> , 2016, 11, 2573-2579.	0.8	17
42	Relationship between circulating tumour cell count and prognosis following chemotherapy in patients with advanced non-small cell lung cancer. <i>Respirology</i> , 2016, 21, 519-525.	1.3	61
43	EGFR mutation status of paired cerebrospinal fluid and plasma samples in EGFR mutant non-small cell lung cancer with leptomeningeal metastases. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 1305-1310.	1.1	52
44	Pneumocystis Pneumonia in Patients with Autoimmune Diseases: A Retrospective Study Focused on Clinical Characteristics and Prognostic Factors Related to Death. <i>PLoS ONE</i> , 2015, 10, e0139144.	1.1	32
45	The role of epidermal growth factor receptor mutations (EGFRm) in NSCLC with leptomeningeal metastasis: A prospective observational study.. <i>Journal of Clinical Oncology</i> , 2015, 33, e19070-e19070.	0.8	0
46	Effect of abundance of EGFR activating mutations and presence of T790M mutation in TKIs-naive tumor specimen on gefitinib response duration in patients with non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, e19077-e19077.	0.8	1
47	Recurrence patterns of advanced non-small cell lung cancer treated with gefitinib. <i>Chinese Medical Journal</i> , 2013, 126, 2235-41.	0.9	14